Value of platelet activation markers as prothrombotic risk indicators

Transfusion Medicine and Hemotherapy

Volumn 34, Issue 1, 2007, Pages 34-42

  Losche W ^a   Heptinstall, S ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Haemostasis; MPV; Platelet activation marker; Platelets; Thrombosis

Indexed keywords

ABCIXIMAB; BETA THROMBOGLOBULIN; BIOLOGICAL MARKER; CD63 ANTIGEN; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN IX; GLYCOPROTEIN V; LIPOCORTIN 5; METALLOPROTEINASE; METALLOPROTEINASE ADAM 13; MONOCLONAL ANTIBODY; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PHOSPHATIDYLSERINE; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTIGEN EXPRESSION; ATHEROSCLEROSIS; CELL INTERACTION; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEART INFARCTION; HEMOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE; MEMBRANE VESICLE; OBESITY; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE VOLUME; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 33846607732     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097497     Document Type: Review

References (157)

1. George JN: Platelets. Lancet 2000;355:1531-1539.
2. Hartwig JH: The platelet: form and function. Semin Hematol 2006;43:S94-100.
3. Ruggeri ZM: Platelet and von Willebrand factor interactions at the vessel wall. Hämostaseologie 2004;24:1-11.
4. Savage B, Sixma JJ, Ruggeri ZM: Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci U S A 2002;99:425-430.
5. Chen J, Lopez JA: Interactions of platelets with subendothelium and endothelium. Microcirculation 2005;12:235-246.
6. Clemetson KJ, Clemetson JM: Platelet collagen receptors. Thromb Haemost 2001;86:189-197.
7. Gibbins JM: Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 2004;117:3415-3425.
8. Hoffman M, Monroe DM III: A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965.
9. Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I: The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004;91:977-985.
10. Balasubramanian V, Grabowski E, Bini A, Nemerson Y: Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002;100:2787-2792.
11. Ni H, Freedman J: Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apher Sci 2003;28:257-264.
12. Steinhubl SR, Moliterno DJ: The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 2005;5:399-408.
13. Monroe DM, Hoffman M, Roberts HR: Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis 1996;7:459-464.
14. Butenas S, Branda RF, van't Veer C, Cawthern KM, Mann KG: Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001;86:660-667.
15. Heemskerk JW, Bevers EM, Lindhout T: Platelet activation and blood coagulation. Thromb Haemost 2002;88:186-193.
16. Solum NO: Procoagulant expression in platelets and defects leading to clinical disorders. Arterioscler Thromb Vasc Biol 1999;19:2841-2846.
17. Lentz BR: Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003;42:423-438.
18. Eilertsen KE, Osterud B: The role of blood cells and their microparticles in blood coagulation. Biochem Soc Trans 2005;33:418-422.
19. Holme PA, Brosstad F, Solum NO: Platelet-derived microvesicles and activated platelets express factor Xa activity. Blood Coagul Fibrinolysis 1995;6:302-310.
20. Camera M, Frigerio M, Marenzi GC, Salvioni A, Biglioli P, Tremoli E: Platelet-associated tissue factor expression in patients with unstable coronary artery disease. J Thromb Haemost 2003;1(suppl 1):OC009.
21. Siddiqui FA, Desai H, Amirkhosravi A, Amaya M, Francis JL: The presence and release of tissue factor from human platelets. Platelets 2002;13:247-253.
22. Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T, Oelschlagel U, Zahler S, Engelmann B: Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001;281:603-609.
23. Scholz T, Temmler U, Krause S, Heptinstall S, Lösche W: Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P. Thromb Haemost 2002;88 (6):1033-1038.
24. Engelmann B, Luther T, Muller I. Intravascular tissue factor pathway - a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 2003;89:3-8.
25. Lösche W: Platelets and tissue factor. Platelets 2005;16:313-319.
26. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci U S A 1999;96:2311-2315.
27. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B: Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585-1598.
28. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA: Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005;106:1604-1611.
29. Furie B, Furie BC: Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004;10:171-178.
30. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, Furie B: P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 1994;91:8767-8771.
31. Lindmark E, Tenno T, Siegbahn A: Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000;20:2322-2328.
32. Freedman JE: Molecular regulation of platelet-dependent thrombosis. Circulation 2005;112:2725-2734.
33. Vorchheimer DA, Becker R: Platelets in atherothrombosis. Mayo Clin Proc 2006;81:59-68.
34. Gawaz M, Langer H, May AE: Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
35. Moake JL: Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
36. Moschcowitz E: Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed diseaase. Proc N Y Pathol Soc 1924;24:21-25.
37. Soejima K, Nakagaki T: Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies. Semin Hematol 2005;42:56-62.
38. Klinger MH, Jelkmann W: Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002;22:913-922.
39. Weyrich AS, Zimmerman GA: Platelets: signaling cells in the immune continuum. Trends Immunol 2004;25:489-495.
40. Gear AR, Camerini D: Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003;10:335-350.
41. Nagata K, Tsuji T, Todoroki N, Katagiri Y, Tanoue K, Yamazaki H, Hanai N, Irimura T: Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). J Immunol 1993;151:3267-3273.
42. Jancinova V, Drabikova K, Nosal R, Danihelova E: Platelet-dependent modulation of polymorphonuclear leukocyte chemiluminescence. Platelets 2000;11:278-285.
43. Lösche W, Dressel M, Krause S, Redlich H, Spangenberg P, Heptinstall S: Contact-induced modulation of neutrophil elastase secretion and phagocytic activity by platelets. Blood Coagul Fibrinolysis 1996;7:210-213.
44. Setzer F, Oberle V, Blaess M, Möller E, Russwurm S, Deigner H-P, Claus RA, Bauer M, Reinhart K, Lösche W: Platelet-derived microvesicles induce differential gene expression in monocytic cells: a DNA microarray study. Platelets 2006;(in press).
45. Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J, Reca R, Janowska-Wieczorek A, Ratajczak MZ: Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002;30:450-459.
46. Diamant M, Tushuizen ME, Sturk A, Nieuwland R: Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest 2004;34:392-401.
47. Born GV: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929.
48. Fox SC, Burgess-Wilson M, Heptinstall S, Mitchell JR: Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter. Thromb Haemost 1982;48:327-329.
49. Bertolino G, Noris P, Balduini CL: Effect of different sample preparation methods on the results of the impedance technique in the study of platelet hyper- and hypo-function in whole blood. Thromb Res 1993;71:89-94.
50. Krause S, May J, Koslowski H, Heptinstall S, Losche W: Enhanced spontaneous platelet aggregation and red blood cell fragility in whole blood obtained from diabetics. Platelets 1991;2:203-206.
51. Losche W, Burgess-Wilson M, Michel E, Heptinstall S, Till U: Diamide induces reversible aggregation of human blood platelets. Thromb Res 1985;40:869-874.
52. Storey RF, Wilcox RG, Heptinstall S: Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency : implications for assay methodology and comparison of different antagonists. Circulation 1998;98:1616-1621.
53. Matzdorff AC, Kuhnel G, Kemkes-Matthes B, Pralle H: Quantitative assessment of platelets, platelet microparticles, and platelet aggregates with flow cytometry. J Lab Clin Med 1998;131:507-517.
54. Fox SC, Sasae R, Janson S, May JA, Heptinstall S: Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry. Platelets 2004;15:85-93.
55. Harrison P, Ault KA, Chapman S, Charie L, Davis B, Fujimoto K, Houwen B, Kunicka J, Lacombe F, Machin S, Raynor R, van HL, van Assendelft OW: An interlaboratory study of a candidate reference method for platelet counting. Am J Clin Pathol 2001;115:448-459.
56. Harrison P, Robinson M, Liesner R, Khair K, Cohen H, Mackie I, Machin S: The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haematol 2002;24:225-232.
57. Madan M, Berkowitz SD, Christie DJ, Smit AC, Sigmon KN, Tcheng JE: Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 2002;144:151-158.
58. Ahn YS, Jy W, Kolodny L, Horstman LL, Mao WW, Valant PA, Duncan RC: Activated platelet aggregates in thrombotic thromboctyopenic purpura: decrease with plasma infusions and normalization in remission. Br J Haematol 1996;95:408-415.
59. Michelson AD, Barnard MR, Krueger LA, Frelinger AL III, Furman MI: Evaluation of platelet function by flow cytometry. Methods 2000;21:259-270.
60. Schmidt V, Hilberg T: ThromboFix platelet stabilizer: advances in clinical platelet analyses by flow cytometry? Platelets 2006;17:266-273.
61. Shattil SJ, Hoxie JA, Cunningham M, Brass LF: Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985;260:11107-11114.
62. Heilmann E, Hynes LA, Burstein SA, George JN, Dale GL: Fluorescein derivatization of fibrinogen for flow cytometric analysis of fibrinogen binding to platelets. Cytometry 1994;17:287-293.
63. Lindahl TL, Festin R, Larsson A: Studies of fibrinogen binding to platelets by flow cytometry: an improved method for studies of platelet activation. Thromb Haemost 1992;68:221-225.
64. Joseph JE, Harrison P, Mackie IJ, Machin SJ: Platelet activation markers and the primary antiphospholipid syndrome (PAPS). Lupus 1998;7(suppl 2):S48-S51.
65. Lundahl TH, Lindahl TL, Fagerberg IH, Egberg N, Bunescu A, Larsson A: Activated platelets and impaired platelet function in intensive care patients analyzed by flow cytometry. Blood Coagul Fibrinolysis 1996;7:218-220.
66. Ghosh K, Khare A, Shetty S, Nair S, Kulkarni B, Mohanty D: Flowcytometric evidence of platelet activation in patients on aspirin following myocardial infarction. Natl Med J India 2006;19:73-74.
67. Meiklejohn DJ, Vickers MA, Morrison ER, Dijkhuisen R, Moore I, Urbaniak SJ, Greaves M: In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001;112:621-631.
68. Roshan TM, Normah J, Rehman A, Naing L: Effect of menopause on platelet activation markers determined by flow cytometry. Am J Hematol 2005;80:257-261.
69. Zeiger F, Stephan S, Hoheisel G, Pfeiffer D, Ruehlmann C, Koksch M: P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis 2000;11:723-728.
70. Yip HK, Liou CW, Chang HW, Lan MY, Liu JS, Chen MC: Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 2005;20:120-128.
71. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR: In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996;93:11877-11882.
72. Ferroni P, Pulcinelli FM, Lenti L, Gazzaniga PP: Is soluble P-selectin determination a more reliable marker of in vivo platelet activation than CD62P flow cytometric analysis. Thromb Haemost 1999;81:472-473.
73. Fijnheer R, Frijns CJ, Korteweg J, Rommes H, Peters JH, Sixma JJ, Nieuwenhuis HK: The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997;77:1081-1085.
74. McEver RP: Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001;86:746-756.
75. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK: Comparison of platelet membrane markers for the detection of platelet activation in vitro and during platelet storage and cardiopulmonary bypass surgery. J Lab Clin Med 1993;121:579-587.
76. Damas C, Vink T, Nieuwenhuis HK, Sixma JJ: The 33-kDa platelet alpha-granule membrane protein (GMP-33) is an N-terminal proteolytic fragment of thrombospondin. Thromb Haemost 2001;86:887-893.
77. Gerdsen F, Weber M, Langer F, Eifrig B, Lindhoff-Last E: Platelet activation markers in patients with venous thromboembolism without predisposing factors. Pathophysiol Haemost Thromb 2005;34:1-5.
78. Fateh-Moghadam S, Li Z, Ersel S, Reuter T, Htun P, Plockinger U, Bocksch W, Dietz R, Gawaz M: Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol 2005;25:1299-1303.
79. Danese S, Scaldaferri F, Papa A, Pola R, Gasbarrini A, Sgambato A, Cittadini A: CD40L-positive platelets induce CD40L expression de novo in endothelial cells: adding a loop to microvascular inflammation. Arterioscler Thromb Vasc Biol 2004;24:e162.
80. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
81. Kalsch T, Nguyen XD, Elmas E, Grebert N, Suselbeck T, Kluter H, Borggrefe M, Dempfle CE: Coagulation activation and expression of CD40 ligand on platelets upon in vitro lipopolysaccharide-challenge in patients with unstable angina. Int J Cardiol 2006;111:217-223.
82. Lee Y, Lee WH, Lee SC, Ahn KJ, Choi YH, Park SW, Seo JD, Park JE: CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999;92:11-16.
83. Martinson J, Bae J, Klingemann HG, Tam Y: Activated platelets rapidly up-regulate CD40L expression and can effectively mature and activate autologous ex vivo differentiated DC. Cytotherapy 2004;6:487-497.
84. Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR: Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991;78:1730-1737.
85. Redlich H, Vickers J, Lösche W, Heptinstall S, Kehrel B, Spangenberg P: Formation of platelet-leukocyte conjugates in whole blood. Platelets 1997;8:419-425.
86. Scholz T, Temmler U, Krause S, Heptinstall S, Losche W: Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P. Thromb Haemost 2002;88:1033-1038.
87. Russwurm S, Vickers J, Meier-Hellmann A, Spangenberg P, Bredle D, Reinhart K, Losche W: Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002;17:263-268.
88. Steiner S, Seidinger D, Huber K, Kaun C, Minar E, Kopp CW: Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol 2003;23:1697-1702.
89. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A: Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999;34:1420-1426.
90. Zhao L, Bath PM, Fox S, May J, Judge H, Losche W, Heptinstall S: The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Curr Med Res Opin 2003;19:178-186.
91. Zhao L, Bath P, Lösche W, Heptinstall S: Platelet-monocyte interaction and GPIIb/IIIa blockade. Thromb Haemost 2004;92:888-890.
92. Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR: Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 1991;78:1760-1769.
93. Lösche W, Scholz T, Temmler U, Oberle V, Claus RA: Platelet-derived microvesicles transfer tissue factor to monocytes but not to neutrophils. Platelets 2004;15:109-116.
94. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI: Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-1537.
95. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL III, Goldberg RJ, Michelson AD: Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002-1006.
96. Hagberg IA, Lyberg T: Evaluation of circulating platelet-leukocyte conjugates: a sensitive flow cytometric assay well suited for clinical studies. Platelets 2000;11:151-160.
97. Kaplar M, Kappelmayer J, Kiss A, Szabo K, Udvardy M: Increased leukocyte-platelet adhesion in chronic myeloproliferative disorders with high platelet counts. Platelets 2000;11:183-184.
98. McGregor L, Martin J, McGregor JL: Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosis. Front Biosci 2006;11:830-837.
99. Camera M, Frigerio M, Toschi V, Brambilla M, Rossi F, Cottell DC, Maderna P, Parolari A, Bonzi R, De Vincenti O, Tremoli E: Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol 2003;23:1690-1696.
100. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B: Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003;17:476-478.
101. Reutelingsperger CP, van Heerde WL: Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci 1997;53:527-532.
102. Reutelingsperger CP, Hornstra G, Hemker HC: Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem 1985;151:625-629.
103. Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT: Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993;81:2554-2565.
104. Tomer A: Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents 2004;18:172-177.
105. Behan MW, Fox SC, Heptinstall S, Storey RF: Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 2005;16:73-80.
106. Chang CP, Zhao J, Wiedmer T, Sims PJ: Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine. J Biol Chem 1993;268:7171-7178.
107. Freyssinet JM: Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003;1:1655-1662.
108. Flaumenhaft R: Formation and fate of platelet microparticles. Blood Cells Mol Dis 2006;36:182-187.
109. Vidal C, Spaulding C, Picard F, Schaison F, Melle J, Weber S, Fontenay-Roupie M: Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 2001;86:784-790.
110. Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A: Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001;85:639-646.
111. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, Hack CE, Sturk A: Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 1999;95:930-935.
112. van der Zee PM, Biro E, Ko Y, de Winter RJ, Hack CE, Sturk A, Nieuwland R: P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 2006;52:657-664.
113. Combes V, Dignat-George F, Mutin M, Sampol J: A new flow cytometry method of platelet-derived microvesicle quantitation in plasma. Thromb Haemost 1997;77:220.
114. Tocchetti EV, Flower RL, Lloyd JV: Assessment of in vitro-generated platelet microparticles using a modified flow cytometric strategy. Thromb Res 2001;103:47-55.
115. Matzdorff AC, Berchner D, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R: Relative and absolute changes of activated platelets, microparticles and platelet aggregates after activation in vitro. Haemostasis 1999;28:277-288.
116. Behan MW, Fox SC, Heptinstall S, Storey RF: Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 2005;16:73-80.
117. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, ten Have K, Eijsman L, Hack CE, Sturk A: Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997;96:3534-3541.
118. Kim HK, Song KS, Lee ES, Lee YJ, Park YS, Lee KR, Lee SN: Optimized flow cytometric assay for the measurement of platelet microparticles in plasma: pre-analytic and analytic considerations. Blood Coagul Fibrinolysis 2002;13:393-397.
119. Shigeta O, Kojima H, Jikuya T, Terada Y, Atsumi N, Sakakibara Y, Nagasawa T, Mitsui T: Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 1997;96:569-574.
120. Galli M, Grassi A, Barbui T: Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost 1996;75:427-431.
121. Morel O, Jesel L, Hugel B, Douchet MP, Zupan M, Chauvin M, Freyssinet JM, Toti F: Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J Thromb Haemost 2003;1:171-177.
122. Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD: Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets 2005;16:368-371.
123. Craft JA, Masci PP, Roberts MS, Brighton TA, Garrahy P, Cox S, Marsh NA: Increased platelet-derived microparticles in the coronary circulation of percutaneous transluminal coronary angioplasty patients. Blood Coagul Fibrinolysis 2004;15:475-482.
124. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY: Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med 2005;37:61-66.
125. Eriksson M, Nelson D, Nordgren A, Larsson A: Increased platelet microvesicle formation is associated with mortality in a porcine model of endotoxemia. Acta Anaesthesiol Scand 1998;42:551-557.
126. Ogura H, Kawasaki T, Tanaka H, Koh T, Tanaka R, Ozeki Y, Hosotsubo H, Kuwagata Y, Shimazu T, Sugimoto H: Activated platelets enhance microparticle formation and platelet- leukocyte interaction in severe trauma and sepsis. J Trauma 2001;50:801-809.
127. Schuerholz T, Sumpelmann R, Piepenbrock S, Leuwer M, Marx G: Ringer's solution but not hydroxyethyl starch or modified fluid gelatin enhances platelet microvesicle formation in a porcine model of septic shock. Br J Anaesth 2004;92:716-721.
128. Soriano AO, Jy W, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, Horstman LL, Kett DH, Schein RM, Ahn YS: Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005;33:2540-2546.
129. Ahn YS, Horstman LL: Idiopathic thrombocytopenic purpura: pathophysiology and management. Int J Hematol 2002;76(suppl 2):123-31.
130. Nomura S, Ishii K, Kanazawa S, Inami N, Uoshima N, Ishida H, Yoshihara T, Kitayama H, Hayashi K: Significance of elevation in celld-erived microparticles after allogeneic stem cell transplantation: transient elevation of platelet-derived microparticles in TMA/TTP. Bone Marrow Transplant 2005;36:921-922.
131. Vanwijk MJ, Nieuwland R, Boer K, van der Post JA, Vanbavel E, Sturk A: Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? Am J Obstet Gynecol 2002;187:450-456.
132. Osumi K, Ozeki Y, Saito S, Nagamura Y, Ito H, Kimura Y, Ogura H, Nomura S: Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost 2001;85:326-330.
133. Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y: Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 2003;89:506-512.
134. Gurney D, Lip GY, Blann AD: A reliable plasma marker of platelet activation: does it exist? Am J Hematol 2002;70:139-144.
135. Blann AD, Lip GY: Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997;128:135-138.
136. Clemetson KJ, Clemetson JM: Platelet GPIb-V-IX comples. Structure, function, physiology and pathology. Semin Thromb Hemost 1995;21:130-136.
137. Strassel C, Moog S, Baas MJ, Cazenave JP, Lanza F: Biosynthesis of platelet glycoprotein V expressed as a single subunit or in association with GPIb-IX. Eur J Biochem 2004;271:3671-3677.
138. Azorsa DO, Moog S, Ravanat C, Schuhler S, Follea G, Cazenave JP, Lanza F: Measurement of GPV released by activated platelets using a sensitive immunocapture ELISA - its use to follow platelet storage in transfusion. Thromb Haemost 1999;81:131-138.
139. Ravanat C, Freund M, Mangin P, Azorsa DO, Schwartz C, Moog S, Schuhler S, Dambach J, Cazenave JP, Lanza F: GPV is a marker of in vivo platelet activation - study in a rat thrombosis model. Thromb Haemost 2000;83:327-333.
140. Blann AD, Lanza F, Galajda P, Gurney D, Moog S, Cazenave JP, Lip GY: Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis - the influence of aspirin and cigarette smoking. Thromb Haemost 2001;86:777-783.
141. Morel O, Hugel B, Jesel L, Mallat Z, Lanza F, Douchet MP, Zupan M, Chauvin M, Cazenave JP, Tedgui A, Freyssinet JM, Toti F: Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004;2:1118-1126.
142. Atalar E, Haznedaroglu IC, Kilic H, Ozer N, Coskun S, Ozturk E, Aksoyek S, Ovunc K, Kirazli S, Ozmen F: Increased soluble glycoprotein V concentration during the acute onset of unstable angina pectoris in association with chronic cigarette smoking. Platelets 2005;16:329-333.
143. Bath PM, Butterworth RJ: Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996;7:157-161.
144. Cameron HA, Phillips R, Ibbotson RM, Carson PH: Platelet size in myocardial infarction. Br Med J (Clin Res Ed) 1983;287:449-451.
145. Martin J, Trowbridge T, Slater D: Mean platelet volume in myocardial infarction. Br Med J (Clin Res Ed) 1983;287:1798.
146. van der Lelie J, Brakenhoff JA: Mean platelet volume in myocardial infarction. Br Med J (Clin Res Ed) 1983;287:1471.
147. Martin JF, Bath PM, Burr ML: Influence of platelet size on outcome after myocardial infarction. Lancet 1991;338:1409-1411.
148. von Ruecker A, Hufnagel P, Dickerhoff R, Murday H, Bidlingmaier F: Qualitative and quantitative changes in platelets after coronary-artery bypass surgery may help identify thrombotic complications and infections. Klin Wochenschr 1989;67:1042-1047.
149. Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R, Wilczynska J, Zielinski A, Meier B, Opolski G: Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005;46:284-290.
150. Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Katdare AD, Inamdar AK: Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol 2006;59:146-149.
151. Kilicli-Camur N, Demirtunc R, Konuralp C, Eskiser A, Basaran Y: Could mean platelet volume be a predictive marker for acute myocardial infarction? Med Sci Monit 2005;11:CR387-CR392.
152. Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W: Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke 2004;35:1688-1691.
153. Butchart EG, Ionescu A, Payne N, Giddings J, Grunkemeier GL, Fraser AG: A new scoring system to determine thromboembolic risk after heart valve replacement. Circulation 2003; 108(suppl 1):II68-74.
154. Coban E, Bostan F, Ozdogan M: The mean platelet volume in subjects with impaired fasting glucose. Platelets 2006;17:67-69.
155. Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T, Lakasas G: Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004;15:475-478.
156. Coban E, Ozdogan M, Yazicioglu G, Akcit F: The mean platelet volume in patients with obesity. Int J Clin Pract 2005;59:981-982.
157. Gyongyosi M, Strehblow C, Sperker W, Hevesi A, Garamvolgyi R, Petrasi Z, Pavo N, Ferdinandy P, Csonka C, Csont T, Sylven C, Declerck PJ, Pavo I Jr, Wojta J, Glogar D, Huber K: Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombogenic response of drug-eluting or bare stent implantation within the first 24 hours. Thromb Haemost 2006;96:202-209.